Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VAK694 · 2 trials · 2 indications
Adverse events will be determined by evaluating clinical, laboratory evaluations, impact on vital signs and impacts on ECGs
| Arm | Type | Description |
|---|---|---|
| Placebo to VAK694 | PLACEBO_COMPARATOR | - |
| VAK694 | EXPERIMENTAL | - |
| Fluticasone propionate | ACTIVE_COMPARATOR | - |
| VAK694 Placebo | PLACEBO_COMPARATOR | VAK694 placebo was administered as a one hour intravenous infusion |
| QAX576 | EXPERIMENTAL | QAX576 was administered intravenously as a 2 hour infusion |
| QAX576 placebo | PLACEBO_COMPARATOR | QAX576 placebo was administered as a 2 hour intravenous infusion |
| Name | Type | Description |
|---|---|---|
| Placebo | BIOLOGICAL | - |
| VAK694 | BIOLOGICAL | - |
| Fluticasone | DRUG | - |
| VAK694 placebo | DRUG | Intravenous infusion |
| QAX576 | DRUG | Intravenous infusion |
| QAX576 placebo | DRUG | Intravenous infusion |
Inclusion Criteria: * Male and female subjects between ages of 18 to 60 in good health * History of atopy for at least 2 years and positive skin prick test to ragweed allergen Exclusion criteria: * History of asthma treated with corticosteroids * Smokers with a smoking history of \> 10 pack/years...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 1 | PHASE3 | LY3650150, Standard therapy for INCS |
| Polyrizon Ltd. | PLRZ | 1 | N/A | Undisclosed |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | - | Undisclosed |
VAK694 is an investigational monoclonal antibody being developed by Novartis AG for the treatment of asthma and allergic rhinitis. It has been studied in clinical trials for these respiratory conditions, though it remains in clinical development and is not yet approved.
VAK694 is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The company has conducted clinical trials to evaluate the safety and efficacy of this investigational monoclonal antibody.
VAK694 has completed a Phase 2 clinical trial for allergic rhinitis and a Phase 1 trial for asthma. It is an investigational drug still in clinical development, and it has not been approved by regulatory authorities for any indication.
VAK694 has been studied in two completed clinical trials. NCT00929968 was a Phase 2 study in 35 subjects with seasonal allergic rhinitis in the United States and Canada. NCT01568762 was a Phase 1 study in 50 patients with asthma in the United States.
VAK694 is a monoclonal antibody, a type of biologic drug designed to target specific molecules involved in disease processes. However, its specific molecular target has not been disclosed in available information, so its exact mechanism of action is not publicly detailed.